Parkside Financial Bank & Trust’s UroGen Pharma URGN Stock Holding History

Parkside Financial Bank & Trust’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66K	Hold	45	–	–	﹤0.01%	2249
2026 Q1	$810	Hold	45	–	–	﹤0.01%	2425
2025 Q4	$1.05K	Hold	45	–	–	﹤0.01%	2334
2025 Q3	$898	Hold	45	–	–	﹤0.01%	2326
2025 Q2	$617	Buy	+45	New	+$432	﹤0.01%	2429

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Parkside Financial Bank & Trust's URGN Position: Q2 2026 in Review

Parkside Financial Bank & Trust held its UroGen Pharma (URGN) position steady in Q2 2026 at 45 shares worth $1.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Parkside Financial Bank & Trust first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Parkside Financial Bank & Trust held 45 shares of UroGen Pharma worth $1.66K as of Q2 2026.
Parkside Financial Bank & Trust left its UroGen Pharma share count unchanged in Q2 2026.
UroGen Pharma made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2249 holding.
Parkside Financial Bank & Trust first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.